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Background: Development and further characterization of animal models for human cancers is important for the
improvement of cancer detection and therapy. Canine bladder cancer closely resembles human bladder cancer in
many aspects. In this study, we isolated and characterized four primary transitional cell carcinoma (K9TCC) cell lines
to be used for future in vitro validation of novel therapeutic agents for bladder cancer.
Methods: Four K9TCC cell lines were established from naturally-occurring canine bladder cancers obtained from
four dogs. Cell proliferation rates of K9TCC cells in vitro were characterized by doubling time. The expression profile
of cell-cycle proteins, cytokeratin, E-cadherin, COX-2, PDGFR, VEGFR, and EGFR were evaluated by immunocytochemistry
(ICC) and Western blotting (WB) analysis and compared with established human bladder TCC cell lines, T24 and
UMUC-3. All tested K9TCC cell lines were assessed for tumorigenic behavior using athymic mice in vivo.
Results: Four established K9TCC cell lines: K9TCC#1Lillie, K9TCC#2Dakota, K9TCC#4Molly, and K9TCC#5Lilly were
confirmed to have an epithelial-cell origin by morphology analysis, cytokeratin, and E-cadherin expressions. The
tested K9TCC cells expressed UPIa (a specific marker of the urothelial cells), COX-2, PDGFR, and EGFR; however they
lacked the expression of VEGFR. All tested K9TCC cell lines confirmed a tumorigenic behavior in athymic mice with
100% tumor incidence.
Conclusions: The established K9TCC cell lines (K9TCC#1Lillie, K9TCC#2Dakota, K9TCC#4Molly, and K9TCC#5Lilly)
can be further utilized to assist in development of new target-specific imaging and therapeutic agents for canine
and human bladder cancer.
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Bladder cancer is the fourth most common cancer in men
and the eighth most common malignancy in women in
the US according to the ACS. An estimated 74,690 new
cases of bladder cancers are expected to occur in 2014 in
the US. An estimated 15,580 bladder cancer-related deaths
will occur in 2014 in the US [1]. The early stage of bladder
cancers is usually surgically removed followed by immuno-
or chemotherapy [2]. However more advanced carcinomas
may often require cystectomy [1]. Precise early detection
of tumors and accurate monitoring of tumor response to* Correspondence: mcekanov@utk.edu
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article, unless otherwise stated.treatment are keys for survival of patients [3]. Up to 70%
of patients with non-muscle-invasive bladder cancer will
develop a local recurrence after transurethral resection of
the bladder tumor [2,4].
Canine transitional cell carcinomas (K9TCC) closely
resemble human invasive urinary bladder cancers [5].
The urinary bladder cancer is an uncommon type of
cancer in dogs, comprising < 2% of all reported canine
malignancies [6]; however 97% of bladder tumors are
malignant at the time of diagnosis. The bladder K9TCC
is the most common neoplasm affecting the urinary tract
of dogs [5]. The histologic and biologic characteristics of
bladder cancers in dogs are similar to bladder cancers in
humans [7,8]. Canine TCC are low grade with superficial
papillary appearance or high grade invasive tumors thatd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to other organs, such as liver and lung predominantly
[5,7,9]. The exact cause of TCC in dogs is still not know,
however a genetic predisposition, pesticides, insecticides,
and second hand smoke are considered major factors
[5,7,9]. Dogs diagnosed with spontaneous tumors offer a
unique model of bladder cancer to study its development
and evaluation of new therapies [10-12]. The chemically-
or genetically-induced TCC tumors in rodent, do not
completely represent human cancer. Very few primary
K9TCC cell lines are currently available [11]; therefore,
there is a further need for new primary K9TCC cell lines
to better understand TCC. Primary TCC cell lines closer
mimic the biological behavior of primary tumors as com-
pared to established immortalized cell lines or cell lines
kept for long time in culture. Cells in long term culture
may accumulate gene mutations.
There are numerous studies that show the correlation
of the expression profiles of tumor markers in K9TCC
with human TCC. The uroplakins are species-conserved
integral membrane proteins that are present on the ap-
ical membrane of the terminally-differentiated superficial
urothelial cells of normal bladder and preserving their
expressions in neoplastic bladder TCC [13-15]. On the
other hand, COX-2 is overexpressed in human bladder
cancers, but not present in normal urothelium [7].
COX-2 expression increases with the stage and grade of
bladder cancer [16]. Various growth factor receptors are
also used as markers for bladder cancer, e.g. platelet-
derived growth factor receptor (PDGFR) is associated
with progression of human bladder cancer [17]. The epi-
dermal growth factor receptor (EGFR) is also overex-
pressed by many carcinomas, including bladder cancers
[18]. Vascular endothelial growth factor receptor (VEGFR)
is expressed not only in endothelial cells, but also in car-
cinoma cells [19,20].
The purpose of this study was to characterize primary
K9TCC cell lines to better understand the mechanisms
of canine and human bladder cancers. Here, we reported
the characterization of four new primary K9TCC cell
lines using Western blotting (WB) and immunocyto-
chemistry (ICC) analysis in vitro. In addition, we con-
firmed tumorigenic behavior of all tested K9TCC cell
lines using athymic mice model in vivo. New K9TCC cell
lines might be used to further evaluate novel imaging
and therapeutic agents for human and canine bladder
cancers.
Methods
Antibodies and other reagents
Antibody for COX-2 was obtained from Cayman Chemical
Corporation (Ann Arbor, MI); antibodies for vimentin,
PDGFR, VEGFR, E-cadherin, cyclin D1, p27, p-ERK1/2,
UPIa, actin, and secondary anti-goat were purchased fromSanta Cruz Biotechnology (Santa Cruz, CA); antibodies
for cytokeratin and Ki67 were obtained from Dako
(Carpinteria, CA); antibody for p65 (NF-κB) was pur-
chased from BD Biosciences (San Jose, California); and
antibody for EGFR, secondary anti-rabbit, and anti-mouse
antibodies were obtained from Cell Signaling (Boston,
MA). All other chemicals and reagents were purchased
from Thermo Fisher Scientific (Pittsburgh, PA), unless
otherwise specified.
Human cell lines
Human transitional cell carcinoma cell lines T24 and
UMUC-3 were purchased from American Type Culture
Collection (ATCC, Manassas, VA). Human T-24 cells
were maintained in DMEM:Ham’s F12 mixture (1:1) and
human UMUC-3 cells were maintained in EMEM media;
respectively, supplemented with 10% fetal bovine serum,
100 I.U. penicillin, and 100 μg/mL streptomycin. Cells
were grown in an atmosphere of 5% CO2 at 37°C.
Canine transitional cell carcinomas (K9TCC)
Primary K9TCC cells were isolated from biopsy specimens
obtained by cystoscopy from client-owned dogs diagnosed
with bladder TCC. The cystoscopy was performed as a
part of diagnosis with best practice of veterinary care
through the Center for Minimally Invasive Procedures at
the College of Veterinary Medicine of the University of
Tennessee. Establishment of primary K9TCC cell lines
procedure was in accordance with approved protocol by
the University of Tennessee IACUC committee with client
consent to use non-utilized tissue specimen for our re-
search. The canine patients with bladder cancers had at
time of diagnosis advance stages of TCC. The non-utilized
biopsy tissues were washed, trypsinized (0.25% trypsin-
EDTA for 2–5 min), and cultured in RPMI-1640 media
with L-glutamine supplemented with 10% fetal bovine
serum, 100 I.U. penicillin, and 100 μg/ml streptomycin in
an atmosphere of 5% CO2 at 37°C for 24 hours. Colonies
of epithelial cells identified under microscope were
transferred into new culture dishes and expanded.
K9TCC cells that progressed through 6 to 9 passages
were characterized. K9TCC cells were cryo-preserved
and recovered for tissue culture to confirm their viabil-
ity. All cell lines have been maintained in the labora-
tory for longer than 15 passages.
Doubling time of K9TCC cells
K9TCC cells were plated in triplicate in 6-well plates.
Cells were trypsinized and counted using a hemocytometer
24, 48, and 72 hours after plating. The doubling time for
the K9TCC cells was calculated using the formula dt = t X
[ln2/ln(Ct/Co), where dt = doubling time, t = time between
cell counts Ct and Co, Co = initial count, Ct = count after
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Cell morphology of K9TCC cells
K9TCC cells were grown in RPMI-1640 media and
allowed to reach 60-70% confluence. The morphology was
examined under phase-contrast microscope with 20 × ob-
jective magnification (Vistavision, VWR) and images were
captured using Moticam camera (VWR) with Motic 5.0
software.
Immunocytochemistry (ICC)
K9TCC cells were plated on 4-chamber slides (Lab-Tek
II, Nalge Nunc, Naperville, IL) and cultured until they
reached 80% to 90% confluence within 24–48 hours and
followed the ICC protocol previously described [21].
Cells were fixed with 2% paraformaldehyde for 10 min at
r.t. and followed by blocking using protein block solu-
tion for 30 min. K9TCC cells were incubated with pri-
mary antibodies (UPIa, vimentin, cytokeratin, COX-2,
PDGFR, VEGFR, EGFR, and Ki67). The details about di-
lutions, exposure times, and temperatures are listed in
the Table 1. Specific secondary antibodies using streptavidin-
biotin detection system (BioGenex Laboratories, Inc.,
Fremont CA) were incubated for 30 min each, followed
by visualization with a DAB substrate. Nuclei of cells were
counter-stained by hematoxylin, slides were mounted,
cover-slipped, and evaluated under Leitz DMRB micro-
scope (Leica). The images were captured by DP73 camera






Anti-UPIa none 1:100 o.n., 4°C 1:50 1 hour, r.t.
Anti-Cytokeratin Proteinase- K 1:800 1 hour, r.t. 1:50 1 hour, r.t.
Anti-EGFR Sodium Citrate 1:100 o.n., 4°C 1:25 1 hour, r.t.
Anti-COX-2 Sodium Citrate 1:500 o.n., 4°C 1:50 1 hour, r.t.
Anti-p65 none 1:500 1 hour, r.t. -
Anti-Vimentin - - 1:100 1 hour, r.t
Anti-Ki67 - - 1:50 1 hour, r.t.
Anti-PDGFR - - 1:25 1 hour, r.t.
Anti-VEGFR - - 1:25 1 hour, r.t.
Anti-phospho-ERK1/2 - - -
Anti-p27 - - -
Notes: o.n. - over night; r.t. - room temperature.microscope using cellSens software (Olympus). The per-
centage of the positive cells were calculated in three fields
with 20 ×magnification. The scoring of staining was done
as following: +++ ≥75%; ++ = 75–50%; + = 50-25%; − ≤25%
positive cells per field of view.
Immunohistochemistry
Dissected tissues from athymic mice and primary tumor
samples from dogs diagnosed with TCC were formalin-
fixed and paraffin-embedded and sectioned at 7 μm.
Hematoxylin and eosin (H&E), and IHC staining was per-
formed following standard protocols [21]. After deparaffi-
nization, the antigen retrieval step was performed as listed
in Table 1, followed by blocking of non-specific binding.
Tissues were incubated with primary antibodies (UPIa,
COX-2, cytokeratin, EGFR, and p65) according the condi-
tions listed in Table 1, followed by the incubation with the
specific secondary antibodies using streptavidin/biotin de-
tection system and visualized by DAB staining. Nuclei
were counter-stained with hematoxylin, slides were cover-
slipped, and evaluated using Leitz DMRB microscope. The
images were captured by DP73 camera attached to micro-
scope using cellSens software (Olympus).
Western blotting (WB)
Human and K9TCC cells were cultured in media with or
without serum for 24 hours. After incubation, the cells
were lysed in ice-cold RIPA buffer supplemented with
protease and phosphatase inhibitors cocktail (0.2 mM





1:1000 o.n., 4°C sc-15173 (C-18) Santa Cruz Biotechnology,
Santa Cruz, CA
1:1000 o.n., 4°C M3515 (AE1/AE3) Dako, Carpinteria, CA
1:1000 o.n., 4°C sc-03 (1005) Cell Signaling Technology,
Boston, MA
1:1000 o.n., 4°C 160126 Cayman Chemical, Ann Arbor, MI
1:1000 o.n., 4°C 610868 BD Transduction Laboratories,
San Jose, CA
. - sc-7557 (C-20) Santa Cruz Biotechnology,
Santa Cruz, CA
- M7240 (MIB-1) Dako, Carpinteria, CA
1:1000 o.n., 4°C SC-338 (C-20) Santa Cruz Biotechnology,
Santa Cruz, CA
1:500 o.n., 4°C 2467 (55B11) Cell Signaling Technology,
Boston, MA
1:1000 o.n., 4°C sc-7383 (E-4) Santa Cruz Biotechnology,
Santa Cruz, CA
1:1000 o.n., 4°C sc-528 (C-19) Santa Cruz Biotechnology,
Santa Cruz, CA
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kept at −80°C until WB analysis performed as previously
described [21]. Briefly, after blocking the membranes were
incubated with primary antibodies (COX-2, EGFR, PDGFR,
VEGFR, p-ERK1/2, cyclin D1, p65, p27, and actin). De-
tails about dilution for each antibody are listed in
Table 1. Membranes were incubated with horseradish
peroxidase-conjugated secondary antibodies (1:3,000
dilution) and immunoreactive bands were visualized
with an enhanced chemiluminescence system (Pierce
Biotechnology, Rockford, IL).
Animal study
All animal studies were performed in accordance with
approved protocols by the UT IACUC committee as
previously described in details [21]. The primary K9TCC
cells were subcutaneously implanted in athymic nude
mice (n = 5/cell line, 1.5×106 cells/mouse with 1:1 Matri-
gel/PBS) to confirm tumorigenic behavior of tested TCC
cells. Human UMUC-3 cells were used as positive controls
(3×106 cells/mouse with 1:1 Matrigel/PBS). The tumors
lengths were measured by a digital caliper once per week
for 3 weeks. After 3 weeks, the xenograft K9TCC tumors
were dissected from mice, fixed, and evaluated by IHC.
Results
Characterization of primary K9TCC tumors
Primary K9TCC cell lines were established from four fe-
male dogs with confirmed diagnosis of urinary tract
TCC. The canine patients with bladder cancers already



























Figure 1 Characterization of K9TCC tumors in vivo. The histology of K9
cytokeratin, EGFR, COX-2 [21], p65, and UPIa in K9TCC#1Lillie, K9TCC#2Dako
scale bar 50 μm. (*) shows normal urethral urothelium in K9TCC#1Lillie, and
tissue sample.Primary K9TCC#1Lillie cell line was established from
biopsy sample obtained from urethra of a 16-year-old
female Pointer dog. The representative histology of the
K9TCC#1Lillie by H&E staining is shown in Figure 1.
The UPIa, a marker for urothelial cells [14], was
expressed in normal urethral urothelial cells (asterisk in
Figure 1) with moderate expression of UPIa detected in
neoplastic K9TCC#1Lillie cells as shown in Figure 1. We
confirmed the urothelial-cell origin of isolated K9TC-
C#1Lillie by positive expression of cytokeratin, E-cadherin
[21], and UPIa using IHC. We confirmed the expression
of COX-2 [21], EGFR, and p65 in this primary tumor by
IHC (Figure 1).
Primary K9TCC#2 Dakota cell line was established from
biopsy sample of urinary bladder of a 13-year-old female
Bichon Fries dog. The representative histology of the
K9TCC#2Dakota by H&E staining is shown in Figure 1.
We confirmed the epithelial-cell origin by positive expres-
sions of cytokeratin, UPIa, and E-cadherin in Figure 1.
The K9TCC#2Dakota cells showed strong COX-2 [21],
p65 (NF-κB), UPIa, and diffused EGFR expressions
(Figure 1).
Primary K9TCC#4Molly cell line was established from
biopsy sample of urinary bladder of a 10-year-old female
Maltese dog. Unfortunately, the immunohistochemistry
analysis of above mentioned markers were not per-
formed in K9TCC#4Molly due to an insufficient size of
biopsy sample obtained during the cystoscopy.
Primary K9TCC#5Lilly cell line was established from
biopsy sample of urinary bladder of a 13-year-old female
mixed-breed dog. The representative histology of theCOX-2EGFR p65
TCC tissues were confirmed by H&E staining. The expressions of
ta, and K9TCC#5Lilly (brown color) detected by IHC. Objective 20× with
inset image shows normal bladder urothelium of K9TCC#5Lilly
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shown in Figure 1. Cells showed the strongest expres-
sions of COX-2, EGFR, and p65 as compared to other
tested K9TCC (Figure 1). The strong expression of UPIa
was detected in normal bladder urothelial cells, espe-
cially in normal terminally-differentiated superficial
urothelial cells (inset in Figure 1 in K9TCC#5Lilly for
UPIa). The decreased intensity of UPIa expression was
detected in neoplastic K9TCC#5Lilly confirming the cell-
origin from bladder urothelium.
Doubling time and morphology of tested primary K9TCC
cells
Cell proliferation of established primary K9TCC cells was
further characterized using doubling time. The doubling
time of the K9TCC cell lines was calculated by counting
trypsinized cells each 24 hours for 3 days. The doubling
time (dt) for K9TCC#1Lillie was dt = 47.4 hours (Figure 2A),
for K9TCC#2 Dakota was dt = 31.96 hours (Figure 2B), for
K9TCC#4Molly was dt =44.69 hours (Figure 2C), and for
K9TCC#5Lilly was dt = 48.3 hours (Figure 2D).
Morphology of tested K9TCC cells was evaluated by
phase-contrast microscope as shown in insets of Figure 2.
All tested K9TCC cells had polygonal morphology, except
K9TCC#4Molly cells that showed more flatten appearance














































0 24 48 72 96
0 24 48 72 96
Figure 2 Doubling time and morphology of primary K9TCC cells. The
(B) K9TCC#2Dakota (passage #5) was dt = 31.96 hours, (C) K9TCC#4Molly (p
was dt = 48.3 hours. Values were represented as the mean ± S.E. (n = 3 for e
were taken by phase-contrast microscope and are shown in insets of graphsingle or multiple nucleoli and cytoplasmic vacuoles
(K9TCC#4Molly).
The expression profile of cancer-related markers in four
primary K9TCC cells
The expressions of several cancer-related markers were
tested in the established primary K9TCC cells and com-
pared to human T24 and UMUC-3 cells by ICC and WB
analysis. The semi-quantitative analysis of the ICC data
are shown in Table 2.
All tested K9TCC cells expressed the urothelium-
specific marker UPIa by ICC as shown in Figure 3. We
tried to detect the expression of UPIa antibody using
WB analysis; however no UPIa band was detected using
this antibody (data not shown). All tested K9TCC cells
showed strong expressions for cytokeratin by ICC, con-
firming the epithelial-cell origin, as shown in Figure 3.
K9TCC had very weak expression of cytoplasmic vimentin
by ICC, therefore confirming that these cells were epithe-
lial and not mesenchymal cell-origin (Figure 3). Ki67 was
used as a marker for cell proliferation and was strongly
detected in three tested K9TCC, except K9TCC#4 Molly
that had only moderate expression of Ki67 by ICC as
shown in Figure 3.
Tyrosine kinase receptors play an important role in
cancer regulation. In our study, we tested the expression
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K9TCC#5Lilly
doubling times for (A) K9TCC#1Lillie (passage #6) was dt = 47.4 hours,
assage #4) was dt = 44.69 hours, and (D) K9TCC#5Lilly (passage #4)
ach time point). The representative images of K9TCC cell morphology
s. Objective 20× with scale bar 50 μm.
Table 2 Semi-quantitative analysis of cancer-related markers by ICC
K9TCC#1Lillie K9TCC#2Dakota K9TCC#4Molly K9TCC#5Lilly
UPIa + +++ + ++
Cytokeratin +++ +++ ++ ++
Vimentin - - - -
Ki67 +++ +++ + +++
PDGFR ++ +++ +++ ++
EGFR + + + +
VEGFR _ _ _ _
COX-2 +++ ++ ++ +++
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K9TCC cells. Our ICC and WB data identified that
PDGFR was more expressed in K9TCC#1Lillie and
K9TCC#2Dakota than in the two other K9TCC#4Molly
and K9TCC#5Lilly as shown in Figure 3 and Figure 4;
respectively. EGFR was moderately expressed in all tested
K9TCC and human TCCs by ICC (Figure 3) as well as by
WB (Figure 4). VEGFR was not detected in tested K9TCC
(Figure 3 and Figure 4) and only moderate expression of
VEGFR was observed in human T24 cells by WB (Figure 4).
The expression of active (phosphorylated) extracellular sig-
nal regulated kinases (p-ERK1/2) as one of the downstream
activators of tyrosine kinase receptors were expressed in all
tested TCC by WB as shown in Figure 4. Interestingly, the
expressions of p-ERK1/2 were less in K9TCC#2Dakota and
UMUC-3 than in the other tested TCC.
Higher levels of COX-2 are associated with higher grade
tumors [22]. COX-2 was highly expressed in all TCC in
perinuclear locations by ICC as shown in Figure 3, with
highest expression of COX-2 in K9TCC#5Lilly detected
by WB (Figure 4). Human T24 cells were used as positive
control and UMUC-3 as negative control for COX-2 ex-
pression (Figure 4). The expression of the p65 (NFκB), as
one of the downstream target of COX-2 signaling path-
way, was detected in all tested TCC as shown in Figure 4.
Cell-cycle-related proteins, such as cyclins and their
inhibitors were also evaluated in tested K9TCC. Cyclin D1
is well known as a cell-cycle regulator of G1 phase of the
cell cycle. As shown in Figure 4, all tested TCC expressed
cyclin D1 with highest expression in K9TCC#4Molly and
K9TCC#5Lilly. Interestingly, the expression of p27, a cell-
cycle dependent kinase inhibitor, was highly expressed in
tested K9TCC except of K9TCC#5Lilly. Actin was used as
a loading control for WB analysis (Figure 4).
Tumorigenic behavior of primary K9TCC cells
In our previously published study, we confirmed in vivo
tumorigenic behavior of two K9TCC cell lines: K9TCC#1Lillie
and K9TCC#2Dakota [21]. Human UMUC-3 cells were
used as a positive control [21]. In this study, we confirmed
tumorigenic behavior of two additional K9TCC cell lines:K9TCC#4Molly and K9TCC#5Lilly as shown in Figure 5.
K9TCC#1Lillie xenograft tumors reached a size of approxi-
mately 1 cm in length within three weeks. K9TCC#2Da-
kota xenograft tumors reached a size of approximately
0.7 cm in length within three weeks. The smallest size of
K9TCC#4Molly and K9TCC#5Lilly xenograft tumors (ap-
proximately 0.4 cm) were observed 3 weeks after inocula-
tion in cells (in Figure 5A). The h-UMUC-3 xenograft
tumors had the largest size of approximately 1.2 cm in
length after three weeks as shown in Figure 5A. The hist-
ology of all tested K9TCC xenograft tumors confirmed that
tumors were of epithelial-cell-origin and formed lobules,
clusters, cysts with partially necrotic centers. K9TCC#4-
Molly xenograft tumors contained large cells as shown by
H&E staining in vivo (Figure 5B) similarly as previously ob-
served in vitro by ICC (Figures 2 and 3). Cytokeratin ex-
pressions were stronger in K9TCC#1Lillie, K9TCC#4Molly,
and K9TCC#5Lilly xenograft tumors as compared to
K9TCC#2Dakota and UMUC-3 xenograft tumors. High
expression of E-cadherin and COX-2 in K9TCC#1Lillie
and K9TCC#2Dakota xenograft tumors and no expression
of COX-2 in UMUC-3 xenograft tumors were confirmed
in our previously published study [21]. Histology of
UMUC-3 xenograft tumor identified that UMUC-3 cells
were not forming any pattern of clusters or lobules,
(Figure 5B) suggesting that UMUC-3 cells are less dif-
ferentiated and more aggressive carcinoma compared to
the established K9TCC carcinomas. This observation
was confirmed by counting the mitotic figures in tested
TCC xenograft tumors. The mitotic figures in tested
K9TCC xenograft tumors was lower, with range from 6 to
8 per high power fields (40×), as compared to h-UMUC-3
cells with approximately 16 mitotic figures/high power
fields (40×).
Discussion
Dogs with spontaneous tumors are still an underex-
ploited tool to make rapid advances in human cancer
prevention, diagnosis, and therapy. Dogs with naturally
occurring cancers provide an important step for success-









































Figure 3 Characterization of primary K9TCC cells in vitro. The expression of UPIa was used to confirm the urothelium cell-origin of established
K9TCC cells K9TCC#1Lillie, K9TCC#2Dakota, K9TCC#4Molly, and K9TCC#5Lilly (brown color) in vitro using ICC. Cytokeratin was expressed in the
membrane in all tested K9TCC cells and confirmed the epithelial-cell origin of established K9TCC cells. Weak expression of vimentin was observed only
in K9TCC#1Lillie and K9TCC#2Dakota cells. Ki67 expression was positive in nucleus, confirming that K9TCC cells were undergoing cell-cycle division. All
tested K9TCC cells showed strong COX-2 and PDGFR expressions. Moderate expressions of EGFR and low expressions of VEGFR were detected in all
tested K9TCC cells. Objective 20× with scale bar 50 μm.
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Press). The average age of the affected dogs with spontan-
eous cancers is 8.4 years, which corresponds to an average
age of 50 years for humans. This suggests that as in
humans, spontaneous carcinomas in dogs are influenced
by age and environmental factors. Cancer heterogeneity
and the ability to study the responses of naturally occur-
ring cancer to therapy in a timely manner are further ad-
vantages of a canine model [23]. The value of this
approach has been increasingly recognized in the studiesidentifying the cancer-associated markers, the environ-
mental risk factors, understanding tumorigenesis, and the
development of novel cancer therapeutics [24,25]. The
major limitation of companion animal models of cancer is
for studies evaluating the monoclonal antibodies for can-
cer therapy [26].
Despite advances in treatment of K9TCC, median sur-
vival times reported for prospective clinical trials have
never exceeded 1 year regardless of the treatment mo-
dality [27]. Surgery and radiation therapy are useful











Figure 4 The expression profile of cancer-related markers in primary K9TCC cells. K9TCC cells were grown in presence and absence of
serum for 24 hours and collected cell lysates were analyzed by WB. The expression levels of PDGFR, EGFR, VEGFR, p-ERK1/2, COX-2, p65, cyclin D1,
and p27 were evaluated. Actin was used as loading control. The arrow shows the specific band for p65.
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[27]. Currently, combined protocols of chemotherapy
with targeted therapies, such as the non-steroidal anti-
inflammatory drugs (piroxicam), show promising inhib-
ition of bladder TCC cells growth in vitro [9]. Piroxicam
in combination with cisplatin or carboplatin induces re-
mission in canine TCC more often than cisplatin [28] or
carboplatin [29] alone.
Fluorocoxib A, a novel optical imaging agent that specif-
ically detects COX-2-expressing cancers [30], was evalu-
ated to detect canine bladder cancer using two primary
K9TCC cell lines: K9TCC#1Lillie and K9TCC#2Dakota
[21]. The results from our previous study showed that
fluorocoxib A selectively binds to COX-2–expressing pri-
mary K9TCC cells in vitro, COX-2–expressing K9TCC xe-
nografts tumors in nude mice in vivo, and heterogeneous
K9TCC during cystoscopy in vivo [21]. Newly established
primary canine and feline oral squamous cell carcinoma
cell lines (K9OSCCAbby and FeOSCCSidney) were
characterized and effects of novel tyrosine kinase inhibi-
tor, Masitinib (AB Sciences) in combination with non-
steroidal anti-inflammatory drugs were evaluated using
this model in vitro [31]. Those are examples of the
utilization of newly established primary canine cancer
cell lines as model for human and canine cancers. Caninecancer models are valuable and efficient for evaluation
and translation of novel imaging and therapeutic drugs to
human medicine.
Despite the disadvantages, cancer cell lines have been,
and will continue to be, the model system of the cancer
in vitro. Very few K9TCC cell lines are currently avail-
able to perform such studies [11], therefore we estab-
lished and characterized four new primary K9TCC cell
lines to be used for in vitro and in vivo studies using
athymic nude mice model. In our study, we evaluated
cell cycle markers of established K9TCC cells as previ-
ously published by Knapp et al. [11], and in addition, we
also evaluated the expression of UPIa and several growth
factor receptor tyrosine kinases by ICC and WB analysis.
We compared the expression of several cancer-related
markers in primary tumor tissues obtained from the
dogs in vivo with primary K9TCC in vitro by ICC and
WB analysis to confirm that expression profiles of pro-
teins were not altered during tissue culture preparation
and expansion of cells. The tumorigenic behavior of
tested K9TCC cell lines was confirmed by formation of
xenograft tumors in the athymic mice. One of the limita-
tion of primary cancer cell lines is that they might stop
proliferating partially due to critical telomere shortening.










































Figure 5 Tumorigenic behavior of K9TCC cells. (A) The primary K9TCC cell were subcutaneously inoculated in athymic mice (n = 5/cell line,
1.5 × 106 cells/mouse with 1:1 Matrigel/PBS) to confirm tumorigenic behavior of tested K9TCC cells. Human UMUC-3 cells were used as positive
controls (3 × 106 cells/mouse with 1:1 Matrigel/PBS). Tumor length was measured after three weeks. Values were represented as the mean +/−S.E.
of tumors length (n = 5 mice). (B) Representative images of H&E and cytokeratin expression (brown color) of K9TCCs and UMUC-3 xenograft
tumors. Objectives 20× with scale bar 50 μm.
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http://www.biomedcentral.com/1471-2407/14/465cell lines with passages# 10 to 20; however we didn’t not
noticed any changes in behavior of those cells in vitro
passing potential “crisis”.
The animal models (rodent and companion animal
models) that recapitulate the nature of human cancers
are major prerequisite for rapid bench-to-bedside trans-
lation of novel anti-cancer drugs and imaging agents
that showed promised in cancer cells in vitro to human
medicine (review In Press). The decision of which model
of cancer to use depends on the stage of drug discovery.
However, the final proof of concept for efficacy and safety
of novel therapeutic and imaging drugs lies in humans.
Conclusions
Spontaneously occurring cancers in pets share similar
molecular and clinical characteristics with human cancers.
Four new primary K9TCC cell lines (K9TCC#1Lillie,
K9TCC#2Dakota, K9TCC#4Molly, and K9TCC#5Lilly)
were characterized as epithelial-cell origin with confirmedcytokeratin, E-cadherin, and UPIa expressions. The posi-
tive expression of COX-2, PDGFR, and EGFR markers
were also confirmed using ICC and WB analysis. The
established primary K9TCC can be used to test novel tar-
geted imaging and therapeutic agents for bladder cancers
in dogs and people.
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